Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 18

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 18
---
 Warrants and we do not expect a market to develop. In addition, we do not intend to                                                                                                      
 apply for the listing of the April 2025 Warrants or Pre-Funded Warrants on any national securities exchange or other trading market.                                                                                                   
 Without an active trading market, the liquidity of the April 2025 Warrants and Pre-Funded Warrants will be limited.                                                                                                                    |
| Transfer Agent and Warrant Agent                   |     | The transfer agent and registrar for our Common Stock                                                                                                                                                                                  
 and the Warrant Agent for the April 2025 Warrants is VStock Transfer, LLC.                                                                                                                                                             |

The information above is based on 18,246,331 shares of Common Stock outstanding as of April 25, 2025, and excludes, as of that date the following:

| ● | 12,873,602                                                                                
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted 
 average exercise price equal to $2.74 per share;                                          |

| ● | 304,125                                                                                    
 shares of Common Stock issuable upon the exercise of stock options issued under our equity 
 incentive plans with a weighted average exercise price equal to $6.95 per share; and       |

| ● | 1,249,024                                                                                  
 shares                                                                                     
 of our Common Stock that are reserved for equity awards that may be granted under our 2024 
 Equity Incentive Plan.                                                                     |

Unless otherwise indicated, all information contained in this prospectus assumes:

| ● | no                                                                                             
 exercise of the outstanding options, warrants, or pre-funded warrants described in the bullets 
 above;                                                                                         |

| ● | no                                                                                           
 exercise of the April 2025 Warrants or the Placement Agent Warrants issued in this offering; 
 and                                                                                          |

| ● | no                                            
 sale of Pre-Funded Warrants in this offering. |

| 5 |

<div align='center'>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

Certain statements in this prospectus may contain “forward-looking statements” within the meaning of the federal securities laws. Our forward-looking statements include, but are not limited to, statements about us and our industry, as well as statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. Additionally, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. We intend the forward-looking statements to be covered